TG Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? TG Therapeutics Inc trades at $49.59 (market cap $7.64B), while Western Alliance Bancorporation trades at $82.22 (market cap $8.89B). The key difference: Western Alliance Bancorporation is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.06% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WAL | |
|---|---|---|
Market Cap | $7.64B | $8.89B |
Sector | Health | Financials |
52-Week High | $59.06 | $96.08 |
52-Week Low | $26.94 | $66.70 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Western Alliance Bancorporation (WAL) trades at $81.64, up 1.44% today, with a neutral technical signal and bullish analyst consensus. The stock shows strong fundamentals, including a P/E of 9.2 and net income margin of 25.43%, supported by recent earnings beats. Recent developments include the launch of WA VenueX, an institutional financial platform, and recognition as Arizona's top bank by Forbes in 2026.
The outlook for WAL is positive, with a consensus price target of $93.86 implying 15% upside, driven by revenue growth and profitability. Risks include negative operating cash flow and high interest expenses. Institutional sentiment is mixed, with some firms reducing stakes, but overall analyst ratings remain heavily bullish.
Trailing returns across standard periods
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →